Jane Street Group LLC Trims Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Jane Street Group LLC cut its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 38.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 79,537 shares of the company's stock after selling 49,476 shares during the quarter. Jane Street Group LLC owned about 0.09% of IDEAYA Biosciences worth $2,520,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in IDYA. Allworth Financial LP grew its stake in IDEAYA Biosciences by 800.0% during the 3rd quarter. Allworth Financial LP now owns 900 shares of the company's stock valued at $29,000 after purchasing an additional 800 shares during the last quarter. Covestor Ltd lifted its holdings in shares of IDEAYA Biosciences by 23,050.0% during the third quarter. Covestor Ltd now owns 926 shares of the company's stock worth $29,000 after purchasing an additional 922 shares during the period. Quest Partners LLC purchased a new stake in IDEAYA Biosciences in the second quarter valued at approximately $41,000. US Bancorp DE increased its holdings in IDEAYA Biosciences by 67.2% in the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company's stock worth $54,000 after buying an additional 689 shares during the period. Finally, Daiwa Securities Group Inc. increased its holdings in IDEAYA Biosciences by 637.9% in the 2nd quarter. Daiwa Securities Group Inc. now owns 1,948 shares of the company's stock worth $68,000 after buying an additional 1,684 shares during the period. 98.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on IDYA shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. UBS Group assumed coverage on shares of IDEAYA Biosciences in a report on Thursday, October 24th. They issued a "buy" rating and a $50.00 price target on the stock. Citigroup cut their price target on IDEAYA Biosciences from $60.00 to $58.00 and set a "buy" rating on the stock in a research report on Tuesday, August 27th. Stifel Nicolaus boosted their price objective on IDEAYA Biosciences from $63.00 to $68.00 and gave the company a "buy" rating in a report on Tuesday, September 10th. Finally, Leerink Partnrs lowered IDEAYA Biosciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $53.67.

IDEAYA Biosciences Stock Down 0.9 %

Shares of IDEAYA Biosciences stock traded down $0.23 during trading hours on Monday, reaching $25.38. 932,821 shares of the company's stock were exchanged, compared to its average volume of 871,569. The business has a fifty day moving average of $28.28 and a two-hundred day moving average of $33.94. The company has a market capitalization of $2.19 billion, a P/E ratio of -10.89 and a beta of 0.79. IDEAYA Biosciences, Inc. has a 1 year low of $24.48 and a 1 year high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.60) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.03. During the same quarter last year, the company posted ($0.46) earnings per share. As a group, research analysts predict that IDEAYA Biosciences, Inc. will post -2.45 EPS for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.